Clinical experience with technetium-99m teboroxime scintigraphy in patients referred for myocardial perfusion evaluation.

A series of 30 patients (25 males, 5 females, age=28–73 years) with a clinical indication of thallium-201 stress/4 hours redistribution scintigraphy has been studied using stress/rest (n=7) or rest/stress (n=23) protocols with technetium-99 m teboroxime (CARDIOTEC, Squibb Diagnostics) in order to assess the clinical usefulness of this new molecule and to compare it to thallium. In all cases coronary artery disease was known or highly suspected, with a history of myocardial infarction in 18 cases (subacute n=6, remote n=12) and/or previous by-pass surgery or PTC A in 5 cases. Medical treatment was not discontinued at the time of stress testing. Coronary angiography was available for 27 patients.